Abstract
Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC). Atractylenolide-I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or paclitaxel to membrane TLR4 of human leukocytes. In this study, AO-I was found to attenuate paclitaxel-induced protein expression of IL-6, VEGF and survivin, and to enhance early apoptosis and growth inhibition in MyD88(+) EOC cells; AO-I was shown to fit into the hydrophobic pocket of human MD-2 and to partially overlap with the binding site of paclitaxel by docking simulations, suggesting that AO-I may block the MD-2-mediated TLR4/MyD88-dependent paclitaxel signaling in MyD88(+) EOC cells. Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-κB pathway.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Apoptosis / drug effects
-
Blotting, Western
-
Carcinoma, Ovarian Epithelial
-
Cell Proliferation / drug effects
-
Cholinergic Antagonists / pharmacology
-
Drug Resistance, Neoplasm / drug effects*
-
Drug Synergism
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Interleukin-6 / metabolism
-
Lactones / pharmacology*
-
Lymphocyte Antigen 96 / chemistry
-
Lymphocyte Antigen 96 / genetics
-
Lymphocyte Antigen 96 / metabolism*
-
Molecular Docking Simulation
-
Myeloid Differentiation Factor 88 / antagonists & inhibitors
-
Myeloid Differentiation Factor 88 / genetics
-
Myeloid Differentiation Factor 88 / metabolism*
-
NF-kappa B / genetics
-
NF-kappa B / metabolism
-
Neoplasms, Glandular and Epithelial / drug therapy*
-
Neoplasms, Glandular and Epithelial / metabolism
-
Neoplasms, Glandular and Epithelial / pathology
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / pathology
-
Paclitaxel / pharmacology*
-
Protein Conformation
-
RNA, Messenger / genetics
-
Real-Time Polymerase Chain Reaction
-
Reverse Transcriptase Polymerase Chain Reaction
-
Sesquiterpenes / pharmacology*
-
Signal Transduction / drug effects
-
Toll-Like Receptor 4 / antagonists & inhibitors
-
Toll-Like Receptor 4 / genetics
-
Toll-Like Receptor 4 / metabolism*
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents, Phytogenic
-
Cholinergic Antagonists
-
Interleukin-6
-
LY96 protein, human
-
Lactones
-
Lymphocyte Antigen 96
-
MYD88 protein, human
-
Myeloid Differentiation Factor 88
-
NF-kappa B
-
RNA, Messenger
-
Sesquiterpenes
-
TLR4 protein, human
-
Toll-Like Receptor 4
-
atractylenolide I
-
Paclitaxel